Artal Group’s Marrone Bio Innovations, Inc. MBII Stock Holding History

Artal Group’s Portfolio MBII Stock Details MBII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,048,679	Closed	-$755K	–	157
2021 Q4	$755K	Buy	+1,048,679	New	+$848K	0.02%	143

Other funds holding MBII

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Artal Group's MBII Position: Q1 2022 in Review

Artal Group sold out of Marrone Bio Innovations, Inc. (MBII) in Q1 2022, closing a stake of 1,048,679 shares — an estimated $755K sold.

Artal Group first reported a position in MBII in Q4 2021 and held it in 1 quarter. The position peaked at $755K in Q4 2021. 71 funds tracked by Wall St. Rank hold MBII as of Q1 2022.

Artal Group reported no remaining Marrone Bio Innovations, Inc. position as of Q1 2022 after selling out during the quarter.
Artal Group sold 1,048,679 Marrone Bio Innovations, Inc. shares in Q1 2022, an estimated $755K.
Artal Group first reported a position in Marrone Bio Innovations, Inc. in Q4 2021 and held it in 1 quarter.
Artal Group's Marrone Bio Innovations, Inc. position peaked at $755K in Q4 2021.
71 funds tracked by Wall St. Rank held Marrone Bio Innovations, Inc. as of Q1 2022.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.